ARAP3

Across TCGA pan-cancer cohorts, ARAP3 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ARAP3 data layer compared with 23 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ARAP3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated ARAP3 expression acts as an unfavorable survival marker, although some lineages such as HNSC and CCRCC show a favorable association.

LUAD, LSCC, and PDAC are the cancer types where ARAP3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	0.719	1.000	<.001	38	view →
LSCC	OS	Quartile	III,IV	0.395	0.839	.014	15	view →
PDAC	DFS	Quartile	II,III,IV	0.309	0.504	.018	14	view →
HNSC	OS	Median	III,IV	0.951	0.763	<.001	10	view →
OV	DFS	Tertile	All	0.612	0.884	.038	8	view →
CCRCC	DFS	Median	III,IV	0.704	0.459	.021	8	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ARAP3–LUAD (OS)

Open the LUAD breakdown →